Measuring patient preferences

Both industry representatives, academics, regulatory and patient groups suffer from a lack of knowledge of the range of methods used in patient preference studies. A recent publication provides insight into the many methods used. 

(Image removed) Vikas Soekhai, PREFER

Systematically collecting patient preference information (PPI) is gaining importance for decision-making in the medical product life cycle. Evidenced-based recommendations are in high demand for how and when PPI can be collected for decision-making. The authors of a recent Drug Discovery Today publication developed a compendium of methods used to explore and elicit patient preferences.

"Many efforts are made to address standards, quality and proper application for collecting patient preference information. The compendium is an updated resource for assessing methods and to determine which methods are most appropriate for different research questions or decisions at different points in the medicinal product and medical device lifecycle. This could help stakeholders choose between methods", says Vikas Soekhai, one of the authors. 

The authors identified 32 unique methods. The trend of mixed methods studies creates a need for further investigation. The authors agree the exploration of patient preference methods provides a foundation for generating recommendations on which methods may be the best suited for different points across the lifecycle.

By Anna Holm

Soekhai V, Whichello C, Levitan B, et al., Methods for exploring and eliciting patient preferences in the medical product life cycle: a literature review, Drug Discovery Today, Avaliable online 8 May 2019.

Full article





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).